Clinical trials: Advanced Solid Tumors Harboring With G12C Mutation, open to volunteers
Advanced Solid Tumors Harboring KRAS G12C Mutation
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation
Researchers are looking for a better way to treat people who have advanced solid cancers with a KRASG12C mutation. Sotorasib is a drug that targets cancer cells which contain mutated KRASG12C protein; it can stop the cancer cells…
- Trial name
- NCT06659341
- Testing
- BAY3498264
- Where
- 11 sites in Australia, Denmark and 3 more
- Volunteers
- 104 people
- Sponsor
- Bayer
Locally Advanced or Metastatic Solid Tumors Harboring KRAS G12C Mutation
GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors
This s a multi-center, open-label phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of GH21 combined with D-1553 in patients with advanced or metastatic solid tumors harboring KRAS G12C…
- Trial name
- NCT06435455
- Testing
- GH21, D-1553
- Volunteers
- 126 people
- Sponsor
- Suzhou Genhouse Bio Co., Ltd.